Know Labs
KNW

$0.2680

1.33%

Market Cap: $28.4M

About: Know Labs Inc is a medical diagnostic. The company is focused on the development, marketing, and sales of proprietary technologies that are capable of uniquely identifying or authenticating almost any substance or material using electromagnetic energy to record, detect, and identify the signature of the substance or material known as Bio-RFID and ChromaID technologies. It is developing a wearable device that will measure blood glucose without fingersticks or microneedles.

Employees: 15

Industrials Measuring & Controlling Devices

0

Funds holding %

of 6,686 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

11% more funds holding

Funds holding: 28 [Q1] → 31 (+3) [Q2]

5% more capital invested

Capital invested by funds: $1.69M [Q1] → $1.78M (+$88.2K) [Q2]

1.77% more ownership

Funds ownership: 3.29% [Q1] → 5.06% (+1.77%) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for KNW.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about KNW published over the past 30 days

Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript

Know Labs, Inc. (NYSE:KNW ) Q3 2024 Results Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Ron Erickson - Chairman and Chief Executive Officer Peter Conley - Chief Financial Officer and Senior Vice President, IP Conference Call Participants Operator Greetings. Welcome to Know Labs's Third Quarter 2024 Earnings Conference Call.

Know Labs, Inc. (KNW) Q3 2024 Earnings Call Transcript

Know Labs, Inc. Reports Third Quarter FY 2024 Results

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024. Financial Highlights: In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prio.

Know Labs, Inc. Reports Third Quarter FY 2024 Results

Know Labs, Inc. Announces Closing of $3.445 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' opt.

Know Labs, Inc. Announces Closing of $3.445 Million Public Offering

Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW) (the “Company”), a leading developer of non-invasive medical diagnostic technology, today announced the pricing of a firm commitment underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from t.

Know Labs, Inc. Announces Pricing of $3.445 Million Public Offering

Sandbox VR Opens First Australian Location August 15 in Gold Coast

BRISBANE, Australia--(BUSINESS WIRE)--Sandbox VR, a full-body virtual reality entertainment experience, is pleased to announce the grand opening of its first Australian location on Thursday, August 15, on the Gold Coast. Sandbox VR Gold Coast is the 50th to open since the company launched in 2017. With over 100k players monthly, Sandbox VR is rapidly growing its global footprint with thriving corporate-owned locations and a robust franchising program. Tickets are on sale now and all guests who.

Sandbox VR Opens First Australian Location August 15 in Gold Coast

Know Labs, Inc. to Host Review of Third Quarter Fiscal Year 2024 Results on August 14, 2024

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced it will host a webcast to review business updates and results for its third quarter of the fiscal year 2024 ended on June 30, 2024, on August 14, 2024, beginning at 1:30 pm PT. Media and investors may access the live audio webcast at this link and also at https://ir.knowlabs.co, beginning at 1:15 pm PT. The webcast will also be available for replay a.

Know Labs, Inc. to Host Review of Third Quarter Fiscal Year 2024 Results on August 14, 2024

Know Labs Publishes Clinical Results in Leading Diabetes Journal

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced the publication of its peer-reviewed study in Diabetes Technology & Therapeutics Journal titled, “A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor.” Diabetes Technology & Therapeutics is a leading, peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge de.

Know Labs Publishes Clinical Results in Leading Diabetes Journal

Know Labs to Present at the American Diabetes Association's Scientific Sessions

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced further interim results from a clinical research study that assessed the accuracy of Know Labs' proprietary non-invasive radiofrequency (RF) dielectric sensor in measuring blood glucose. Participants with prediabetes and Type 2 diabetes were studied and venous blood was used as a comparative reference. The study found that the accuracy of Know Labs'.

Know Labs to Present at the American Diabetes Association's Scientific Sessions

Know Labs Joins the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive medical diagnostic technology, today announced that it has joined the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University's Diagnostics Accelerator. The Wyss Institute at Harvard University is a translational research institute, developing disruptive innovation for healthcare and sustainability, powered by a multidisciplinary bioenginee.

Know Labs Joins the Industrial Participant Program of the Wyss Institute for Biologically Inspired Engineering at Harvard University

Know Labs Appoints Chris Somogyi as President, International

SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (NYSE American: KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's “Skunkworks” Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extens.

Know Labs Appoints Chris Somogyi as President, International

See News Rankings